CNC

Centene's FY2025 is ugly on the surface: a $6.67B net loss versus a $3.31B profit the year before, a -$13.53 diluted EPS, a -4.4% operating margin and a -33.4% ROE — all while revenue actually grew 20% to $175B. The cause is specific and, importantly, operational rather than structural: the 10-K attributes the collapse to an HBR (medical-loss) spike where premiums lagged acuity. Late-Q2 2025 actuarial data implied materially higher Marketplace morbidity, gutting expected net risk-adjustment revenue, and Medicaid costs ran hot on behavioral health, home health and high-cost specialty drugs. A $513M Magellan impairment added insult. Because managed-care margins are razor-thin, small HBR moves swing earnings violently — which cuts both ways on the way back up as state rates reset to acuity.

Crucially, this is not a solvency story. Operating cash flow was still positive at $5.09B, cash rose 27% to $17.9B, equity remains $20.0B against $17.4B long-term debt, and leverage at 2.84x liabilities/equity is unremarkable for an insurer. At $65.73 the stock trades at ~0.2x sales — washed out, with much of the bad news arguably priced in. If rate adjustments catch up to medical cost trend, normalized earnings power on a $175B book is substantial, and the cash generation funds the wait.